Prognostic value of multimodal assessment of congestion in acute heart failure

Rev Clin Esp (Barc). 2021 Apr;221(4):198-206. doi: 10.1016/j.rceng.2019.10.013. Epub 2021 Feb 26.

Abstract

Background: A physical examination has limited performance in estimating systemic venous congestion and predicting mortality in patients with heart failure. We have evaluated the usefulness of the N-terminal prohormone of brain natriuretic peptide (NT-proBNP), cancer antigen 125 (CA125), lung ultrasound findings, relative plasma volume (rPV) estimation, and the urea/creatinine ratio as surrogate parameters of venous congestion and predictors of mortality.

Methods: This work is a retrospective study of 203 patients admitted for acute heart failure in a tertiary hospital's internal medicine department with follow-up in a specialized outpatient clinic between 2013 and 2018. Clinical data were collected from hospital records. Treatment was decided upon according to the clinical judgment of each patient's attending physician. The main outcome measure was all-cause mortality at one year of follow-up.

Results: Patients' mean age was 78.8 years and 47% were male. A total of 130 (65%) patients had chronic heart failure, 51 (26.2%) patients were in New York Heart Association class III-IV, and 116 (60%) patients had preserved left ventricular ejection fraction. During follow-up, 42 (22%) patients died. Values of NT-proBNP≥3804pg/mL (HR 2.78 [1.27-6.08]; p=.010) and rPV≥-4.54% (HR 2.74 [1.18-6.38]; p=.019) were independent predictors of all-cause mortality after one year of follow-up.

Conclusions: NT-proBNP and rPV are independent predictors of one-year mortality among patients hospitalized for decompensated heart failure.

Keywords: CA125; Congestión sistémica; Ecografía pulmonar; Estado de volumen plasmático; Lung ultrasound; NT-proBNP; Plasma volume status; Systemic congestion.

MeSH terms

  • Aged
  • CA-125 Antigen
  • Heart Failure*
  • Humans
  • Male
  • Prognosis
  • Retrospective Studies
  • Stroke Volume
  • Ventricular Function, Left*

Substances

  • CA-125 Antigen